Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
882.20 DKK | -2.35% | -0.93% | +26.37% |
Business description: Novo Nordisk A/S
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Number of employees: 69,260
Sales by Activity: Novo Nordisk A/S
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Diabetes and Obesity Care | 103B | 108B | 122B | 156B | 215B |
Rare Disease | 19.18B | 18.93B | 19.2B | 20.54B | 17.16B |
Geographical breakdown of sales: Novo Nordisk A/S
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
The US | 57.49B | 57.82B | 63.01B | 84.66B | 128B |
EMEA | - | 34.3B | 37.71B | 44.24B | 50.87B |
Rest of World | - | 17.45B | 19.81B | 25.4B | 28.08B |
Region China | 12.84B | 14.08B | 16.02B | 16.21B | 16.69B |
North America (Excl. US) | 2.97B | 3.29B | 4.25B | 6.45B | 9.1B |
Africa, Asia, Middle East and Oceania (AAMEO) | 14.09B | - | - | - | - |
Latin America | 4.92B | - | - | - | - |
Japan & Korea | 6.45B | - | - | - | - |
Europe | 23.26B | - | - | - | - |
Managers: Novo Nordisk A/S
Director | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 01/91/01 | |
Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Chief Tech/Sci/R&D Officer | 54 | 01/99/01 | |
Chief Operating Officer | 54 | 01/92/01 |
Members of the board: Novo Nordisk A/S
Manager | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/15/19 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23/17/23 |
Helge Lund
CHM | Chairman | 62 | 23/17/23 |
Director/Board Member | 49 | 22/18/22 | |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22/18/22 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01/18/01 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
Laurence Debroux
BRD | Director/Board Member | 55 | 21/19/21 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25/21/25 |
Director/Board Member | 59 | 24/22/24 |
Holdings: Novo Nordisk A/S
Name | Equities | % | Valuation |
---|---|---|---|
NOVO NORDISK A/S 0.40% | 13,563,880 | 0.40% | 1,888,266,934 $ |
NNIT A/S 17.50% | 4,375,000 | 17.50% | 69,858,731 $ |
INNATE PHARMA 12.13% | 9,817,546 | 12.13% | 22,712,107 $ |
Company details: Novo Nordisk A/S
Group companies: Novo Nordisk A/S
Name | Category and Sector |
---|---|
Novo Nordisk India Pvt Ltd.
Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
NNE A/S
NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark. |
Engineering & Construction
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Health Care AG
Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-2.35% | -0.93% | +35.64% | +174.23% | 597B | ||
-0.13% | -1.73% | +58.41% | +293.29% | 816B | ||
-0.55% | +0.81% | +2.27% | +0.85% | 402B | ||
-0.26% | -0.85% | +25.33% | +79.10% | 342B | ||
+0.30% | +3.43% | +10.04% | +65.51% | 300B | ||
+0.83% | -0.15% | +4.05% | -21.73% | 253B | ||
-0.94% | -3.67% | +10.51% | +47.04% | 244B | ||
+0.01% | +0.58% | +6.54% | +26.60% | 234B | ||
+0.04% | +0.89% | +26.51% | +51.75% | 179B | ||
-0.27% | +0.30% | -11.56% | -32.22% | 169B | ||
Average | -0.15% | -0.04% | +16.77% | +68.44% | 353.59B | |
Weighted average by Cap. | -0.33% | +0.01% | +25.29% | +114.92% |
Sector
- Stock Market
- Equities
- NOVO B Stock
- Company Novo Nordisk A/S
MarketScreener is also available in this country: United States.
Switch edition